CDLX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
32.9M
-10.8%
36.9M
+7.5%
34.3M
-38.8%
56.1M
+19.4%
47.0M
Cost of Revenue
3.2M
+19.1%
2.6M
+2.6%
2.6M
+103.5%
-72744000
-1858.8%
4.1M
Gross Profit
29.7M
-13.2%
34.2M
+7.9%
31.7M
-75.4%
128.8M
+200.8%
42.8M
Operating Expenses
35.1M
-11.4%
39.7M
-0.8%
40.0M
-70.3%
134.9M
+23.8%
109.0M
R&D
3.7M
-33.0%
5.5M
-13.8%
6.4M
-19.3%
8.0M
+6.6%
7.5M
SG&A
13.8M
-4.8%
14.5M
-3.9%
15.0M
-12.8%
17.3M
+2.7%
16.8M
Operating Income
-5421000
+0.4%
-5441000
+34.2%
-8274000
-35.8%
-6095000
+90.8%
-66129000
EBITDA
-1239000
+10.2%
-1380000
+64.2%
-3856000
-674.7%
671.0K
+182.5%
-813000
Net Income
-8947000
+39.9%
-14876000
-232.1%
-4480000
+45.7%
-8250000
+88.6%
-72673000
EPS (Basic)
$-1.52
+41.1%
$-2.58
-222.5%
$-0.80
+47.4%
$-1.52
+88.8%
$-13.59
EPS (Diluted)
$-1.52
+41.1%
$-2.58
-222.5%
$-0.80
+47.4%
$-1.52
+88.8%
$-13.59
Shares (Diluted)
5.9M
+2.5%
5.8M
+4.9%
5.5M
+1.0%
5.4M
+1.6%
5.3M
Cardlytics (CDLX) — Financials